deCODE : Gentechnik mit Phantasie "Allianz von deCODE mit Roche" - 500 Beiträge pro Seite

[kammler]

deCODE and Roche Sign Landmark Alliance to Develop Integrated DNA-based
Diagnostic Tools and Related Services and Software



REYKJAVIK, Iceland, July 2 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN
; Nasdaq Europe) today announced that, effective June 29, 2001, it has
signed with F. Hoffmann-LaRoche Ltd. AG the definitive terms of their
landmark five-year alliance to develop and market DNA-based diagnostics
for major diseases. The companies announced the signing of a letter of
intent to establish this alliance in March.

The worldwide market for genomic diagnostics is estimated to grow to $4
billion over the next ten years, and Roche aims to build on its global
leadership in the field of diagnostics to capture a significant share of
this market. Roche`s alliance with deCODE is a key component of its
long-term strategy. The companies estimate that the total value of the
collaboration to deCODE could exceed $300 million.

The alliance is also a central element in deCODE`s ongoi

[kammler]

... sorry ! Anbei noch einmal der vollstaendige Text !!!



deCODE and Roche Sign Landmark Alliance to Develop Integrated DNA-based
Diagnostic Tools and Related Services and Software



REYKJAVIK, Iceland, July 2 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN
; Nasdaq Europe) today announced that, effective June 29, 2001, it has
signed with F. Hoffmann-LaRoche Ltd. AG the definitive terms of their
landmark five-year alliance to develop and market DNA-based diagnostics
for major diseases. The companies announced the signing of a letter of
intent to establish this alliance in March.

The worldwide market for genomic diagnostics is estimated to grow to $4
billion over the next ten years, and Roche aims to build on its global
leadership in the field of diagnostics to capture a significant share of
this market. Roche`s alliance with deCODE is a key component of its
long-term strategy. The companies estimate that the total value of the
collaboration to deCODE could exceed $300 milli

[Erbse1]

Habe hier den vollständigen Text. Ich bin auch mal auf die Eröffnung in Amerika gespannt. Freitag waren es ja schon mal über 40% . Liebe Grüße Erbse1.
------------------------------------------------------------
deCODE and Roche Sign Landmark Alliance to Develop Integrated DNA-based Diagnostic Tools and Related Services and Software
July 02, 2001 01:30:00 AM ET

The Alliance Has a Total Potential Value to deCODE of Over $300 Million

REYKJAVIK, Iceland, July 2 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN; Nasdaq Europe) today announced that, effective June 29, 2001, it has signed with F. Hoffmann-LaRoche Ltd. AG the definitive terms of their landmark five-year alliance to develop and market DNA-based diagnostics for major diseases. The companies announced the signing of a letter of intent to establish this alliance in March.

The worldwide market for genomic diagnostics is estimated to grow to $4 billion over the next ten years, and Roche aims to build on its global leadership in the field of diagnostics to capture a significant share of this market. Roche`s alliance with deCODE is a key component of its long-term strategy. The companies estimate that the total value of the collaboration to deCODE could exceed $300 million.

The alliance is also a central element in deCODE`s ongoing strategy of creating value by turning its unique research platform and achievements into products on the market. The alliance builds on key deCODE and Roche assets: deCODE`s comprehensive population genomics resources and bioinformatics expertise, and Roche`s preeminence in the development and marketing of molecular diagnostics. In addition to the development of novel DNA-based diagnostic and predisposition screening products, the companies hope to develop point-of-care informatics products that can assist doctors in evaluating the results of DNA-based diagnostic tests.

Kari Stefansson, CEO of deCODE genetics, said, "We are very excited to be able to bring together our gene research and bioinformatics know-how with the development and marketing expertise of the world`s leading diagnostics company. We believe that these tools and decision-support systems will become a fundamental component of future medicine, and that this alliance will create significant value for deCODE going forward."

deCODE genetics ( www.decode.com ), based in Reykjavik, Iceland, is conducting research into the inherited causes of common diseases. The company has three main business units: discovery services -- including disease-gene research, drug target identification and pharmacogenomic services; database services; and bioinformatics tools and services. deCODE is using its population approach to turn raw genomics data into products and services for the global healthcare industry.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified in deCODE`s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. deCODE undertakes no obligation to publicly release any revisions to these forward-looking statements resulting from events or circumstances after the date hereof.

Contacts:
deCODE genetics F. Hoffmann-LaRoche
Edward Farmer Rolf Schlaepfer
[phone] [phone]
[e-mail]
------------------------------------------------------------

[Erbse1]

Habe eben noch den Text bei comdirect in Deutsch gefunden.
-----------------------------------------------------------
Roche und deCODE schließen Allianz
Die Roche Holding AG und die deCODE genetics Inc. stimmten der geplanten fünfjährigen Allianz zu. Nachdem im März bereits Absichtserklärungen abgegeben wurden, wurde die Vereinbarung am 29.06. unterzeichnet.


Dabei wollen die Unternehmen gemeinsam auf DNA basierende Diagnostiken für allgemeine Krankheiten entwickeln und verkaufen. DeCODE ist führend in der Forschung von erblichen Ursachen von allgemeiner Krankheiten. Das Volumen der Zusammenarbeit wird auf über 300,0 Mio. Dollar geschätzt.


Roche will seine Führung im Bereich Genom-Diagnostik ausbauen und sich bedeutende Marktanteile aneignen. Der Weltmarkt hiefür wird Schätzungen zufolge in den nächsten zehn Jahren auf 4,0 Mrd. Dollar ansteigen.


Die Aktien von Roche notieren aktuell bei 86,00 Euro. Die Aktien von deCODE siegen an der Nasdaq um 42,31 Prozent und schlossen bei 12,31 Dollar.

------------------------------------------------------------

[Erbse1]

Hier noch ein update zu der Meldung von heute Morgen.
Liebe Grüße Erbse1
------------------------------------------------------------
UPDATE 1-DeCODE may get $300 mln under new Roche deal
July 02, 2001 07:09:00 AM ET

(Adds detail, analyst comment, shares, changes dateline)

LONDON, July 2 (Reuters) - Iceland`s deCODE Genetics Inc (DCGN) said on Monday it could receive as much as $300 million under a new diagnostics deal with Swiss healthcare group Roche Holding AG . The five-year agreement, covering the development and marketing of DNA-based diagnostic tests for major diseases, was first announced in March but financial details were only revealed following signing of definitive terms last week.

It builds on an earlier collaboration between the two firms, worth up to $200 million, to develop new drugs using deCODE`s genomic skills. DeCODE has so far delivered three drug targets for schizophrenia, stroke and narrowed arteries under that deal.

DeCODE has exclusive access to Iceland`s health records and is analysing the population`s unique genetic composition, which has remained stable since the Vikings arrived in the ninth and 10th centuries, to uncover the genetic basis of disease.

Chief Executive Kari Stefansson said the latest tie-up with Roche -- the world`s largest diagnostic company -- would create "significant value" in the years ahead. Diagnostic kits are faster to develop than new drugs, offering medium-term income while more valuable therapeutic products are awaited.

Under the deal, deCODE will receive some $15 million a year in fixed funding, including an upfront fee of $5 million, plus a royalty on sales of products that eventually come to market, according to analysts who attended a briefing in Reykjavik.

The first DNA diagnostic product is expected to be available by the end of next year.

"This new collaboration confirms Roche`s positive attitude to the progress made by deCODE in its disease-gene discovery work," said Ian Smith, biotechnology analyst at Lehman Brothers, who rates deCODE a "buy".

Roche and deCODE estimate the worldwide market for genomic diagnostics could grow to $4 billion over the next 10 years -- still a fraction of the more than $300 billion spent on pharmaceuticals in major markets each year.

Shares in deCODE, which listed on Nasdaq in the U.S. and in Europe last July, hit a high for the current year of $12.75. The advance followed strong gains in New York on Friday, where the stock was supported by demand from funds because of its inclusion in the Russell 2000 index.

DeCODE expects to receive revenues of $40 million this year but is unlikely to make a profit before 2003 or 2004. REUTERS

------------------------------------------------------------

[pungnee]

Dna diagnostic wäre in Island eher bei Kabeljau nötig.dieleute haben im sommer zu viel Photonenbeschuss,im Winter zu wenig.Das macht depressiv und krank(äthanolmissbrauch inklusive).Sind nicht arm,daher ein ideales Betätigungsfeld für Bürokraten und Genetiker,bei denpaar Einwohnern.Kaufe mir einige Dutzend 936848.Solange dort noch massiver Vulkanismus (mit besten Thermalquellen )sprudeln werden sich die Krankenscheine nicht multiplizieren

[Erbse1]

Hier kurz eine interessante Meldung. Decode scheint sich damit neue Geschäftsfelder zu erschließen. Die bisherige kritisierte einseitige Ausrichtung auf Roche ist dann nicht mehr gegeben. Decode sollte man im Auge behalten.
Liebe Grüße Erbse1.
------------------------------------------------------------
Personalizing Medicine: deCODE and Affymetrix to Collaborate on DNA-based Tests to Optimize the Effectiveness of Treatments for Major Diseases
July 24, 2001 02:00:00 AM ET

Pharmacogenomics Alliance Aims to Benefit Patients, Payers and the Pharmaceutical Industry

REYKJAVIK, Iceland and SANTA CLARA, Calif., July 24 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN; Nasdaq Europe) and Affymetrix, Inc. AFFX today announced that they have signed a collaboration to develop DNA-based tests to predict the responsiveness of individual patients to treatments for common diseases. Such tests promise to play an important role in delivering more effective medicine.

Utilizing deCODE`s unique population-based approach to pharmacogenomics and Affymetrix` GeneChip(R) technology, the collaboration will initially focus on conducting gene expression analysis to understand the response to drugs used in the treatment of common conditions affecting millions of people around the world. These include high-cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraine. Clinical work under this new collaboration will be performed by Encode, a wholly-owned deCODE subsidiary conducting pharmacogenomics research and clinical trials for a growing list of leading pharmaceutical companies. Affymetrix and deCODE, through its subsidiary Encode, will share the revenues from the sale of tests developed under the collaboration.

"Through this alliance we are well-positioned to take a leading role in delivering more personalized treatments for common diseases," said Kari Stefansson, Chief Executive Officer of deCODE. "Pharmacogenomic tests such as those we plan to develop will become a standard part of future healthcare. Our companies have a unique combination of expertise for meeting the demands of this growing market, and we at deCODE are very pleased to be leveraging our pharmacogenomics platform with a trusted partner and leader in gene expression technology."

"By combining deCODE`s population resources for pharmacogenomics with Affymetrix` high-density GeneChip platform, we hope to expand the clinical use of gene expression profiles to predict drug response," said Stephen P.A. Fodor Ph.D., Chairman and Chief Executive Officer of Affymetrix. "We believe these studies will generate valuable new indicators of disease, thereby contributing to the development of more effective therapies."

About pharmacogenomics

DNA-based pharmacogenomic tests are one of the great promises of genetics. Patients can gain greater comfort by knowing that the drugs they are prescribed are right for them, with the possibility of reduced side effects. Healthcare providers will gain from the improved safety and cost effectiveness of prescriptions. The pharmaceutical industry can utilize such tests to further streamline individual drug development and approval processes, enabling new drugs to reach the market faster.

This alliance will enable the companies to leverage existing capabilities. Using the Affymetrix GeneChip platform, deCODE has already identified a gene expression pattern that can accurately predict glucocorticoid response in asthma patients. deCODE recently signed an agreement with Genmab A/S to develop a pharmacogenomic test for a novel treatment for rheumatoid arthritis.

deCODE genetics (http://www.decode.com), based in Reykjavik, Iceland, is conducting research into the inherited causes of common diseases. The company has three main business units: discovery services -- including disease-gene research, drug target identification and pharmacogenomic services; database services; and bioinformatics tools and services. deCODE is using its population approach to turn raw genomics data into products and services for the global healthcare industry. Encode, launched as a wholly-owned subsidiary in November 2000, is a full-service CRO conducting pharmacogenomic studies and clinical trials for major pharmaceutical and biotechnology companies.

Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. Affymetrix customers include pharmaceutical, biotechnology, agrochemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. The Company`s GeneChip(R) system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy to use platform. Additional information on Affymetrix and GeneChip array technology can be found at http://www.affymetrix.com.
------------------------------------------------------------

[Erbse1]

Hab noch einen kleine Beitrag bei WO gefunden.
------------------------------------------------------------
Affymetrix und deCode kooperieren auf zukunftsträchtigem Gebiet



Pharmacogenomics ist ein schwieriger Begriff für ein Gebiet, mit dem jeder schon in Berührung gekommen ist: Medikamente wirken bei einzelnen Menschen unterschiedlich, zum Leidwesen vieler oft gar nicht. Außerdem gibt es so genannte „Nebenwirkungen“ – unerwünschte, zum Teil schädigende Wirkungen, die gesunde Teile des Körpers in Mitleidenschaft ziehen.

Das liegt – so vermuten Wissenschaftler – an winzigen genetischen Unterschieden der Menschen. Diese so genannten SNPs (single nucleotide polymorphism) stehen im Fokus zahlreicher Forschungsbemühungen. Das Ziel ist, verlässliche Voraussagen über die Wirksamkeit eines Medikamentes zu treffen. Auf dieser Basis soll eine individualisierte Behandlung entstehen. Das ist zunächst vor allem für die Medikamentenentwickler von großer Bedeutung, wo die Hoffnung auf die Vermeidung teurer Fehlschläge besteht.

Die Kooperation von Affymetrix und deCode Genetics zielt auf diesen Bereich. Es soll ein DNA-Test entwickelt werden, der die Reaktion von Patienten auf Wirkstoffe vorhersagen soll. Dabei geht es unter anderem um Krankheiten wie Krebs, Migräne, Shizophränie, Asthma und Depressionen. Nach Ansicht von Kari Stefansson, CEO von deCode, werden derartige Tests, wie ihn die beiden Partner entwickeln wollen, in Zukunft zum Standard im Medizinbereich werden.

Autor: Alexander Apel, 12:44 24.07.01
------------------------------------------------------------